Pulmatrix (NASDAQ:PULM) Stock Crosses Below 50 Day Moving Average – Should You Sell?

Posted by Tristan Rich on Sep 9th, 2026

Shares of Pulmatrix, Inc. (NASDAQ:PULM – Get Free Report) crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $1.62 and traded as low as $1.36. Pulmatrix shares last traded at $1.3950, with a volume of 7,375 shares changing hands.

Analyst Ratings Changes

Separately, Weiss Ratings cut shares of Pulmatrix from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 14th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of “Sell”.

Get Our Latest Report on PULM

Pulmatrix Trading Up 0.4%

The stock’s 50-day moving average price is $1.62 and its two-hundred day moving average price is $1.63. The stock has a market capitalization of $5.09 million, a P/E ratio of -1.27 and a beta of 1.90.

Pulmatrix (NASDAQ:PULM – Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($2.00) by $1.71.

Institutional Investors Weigh In On Pulmatrix

Large investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP bought a new stake in Pulmatrix in the 3rd quarter valued at about $52,000. DRW Securities LLC bought a new position in Pulmatrix during the fourth quarter worth about $46,000. Finally, BlackRock Inc. purchased a new position in shares of Pulmatrix in the second quarter worth about $93,000. Hedge funds and other institutional investors own 11.84% of the company’s stock.

Pulmatrix Company Profile

(Get Free Report)

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).